Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Yutaka Niihara, MD, MPH
Researcher Professor of Medicine
David Geffen School of Medicine at UCLA
1124 West Carson Street C-1, Room 12
Torrance, California, United States
Dr. Niihara has been involved in patient care and research for sickle cell disease for most of his career, and is the principal inventor of the patented L-glutamine therapy for treatment of sickle cell disease in which he co-founded the bio-pharmaceutical company, Emmaus Life Sciences, Inc. It is now in phase III clinical trial involving 32 sites throughout US with FDA Drug Designation and Fast Track Designation. Additionally, his laboratory focuses on regenerative medicine using cell sheet technology. This treatment uses autologous progenitor cell sheets to repair damaged organs such as cornea epithelium and myocardium. Currently, he is the Professor of Medicine at the David Geffen School of Medicine at UCLA. His areas of research are sickle cell disease, cancer & carcinogenesis, blood & blood products & transfusions, biological markers and oncology specialized techniques in research such as red cell enzyme studies and red cell nucleotide analysis.
+myBinderRelated Content
-
Steven Ambrusko, MD, MSDr. Ambrusko is a pediatric hematologist...
-
Global Sickle Cell Disease Treatment Market 2019–2023| Evolving Opportunities with ADDMEDICA and Bristol-Myers Squ...The global sickle cell disease treatment...
-
Sickle Cell Disease: Reducing the Global Disease BurdenSickle cell disease has been largely an ...
-
Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)GBT440 is First Potential Treatment for ...
-
Shelley Crary, MD, MSDr. Shelley Crary received her undergrad...
-
University of Pittsburgh Medical CenterPeople with inherited blood disorders re...
-
Secondhand smoke is associated with more frequent hospitalizations in children with sickle cell diseaseTobacco smoke exposure has been associat...
